Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter
Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter
Stereotaxis Inc (NYSE:STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE:ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation systems.
Stereotaxis and Abbott have completed the integration of their technologies and performed testing demonstrating joint compatibility.
The integrated technologies are cleared for use in Europe, with additional regulatory clearances expected in the coming months.
Concurrently, the FDA approved Abbott's TactiFlex Ablation Catheter, Sensor Enabled. The company says it is the world's first ablation catheter with a flexible tip and contact force technology.
It is used to perform an ablation procedure to treat atrial fibrillation (AFib), the most common abnormal heart rhythm. The TactiFlex catheter can result in reduced procedure times and better safety than the company's previous-generation catheters.
The TactiFlex catheter uses a tip design with a laser-cut pattern that flexes when in contact with the heart wall, thus helping direct fluid to the treated tissue and allowing for more accurate positioning of the catheter – providing up to two times higher stability in a beating heart – for consistent therapy delivery.
Tuesday, the FDA approved Abbott's spinal cord stimulation devices for chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
Price Action: STXS shares are up 34.7% at $2.28, and ABT shares are up 0.34% at $108.84 on the last check Friday.
Stereotaxis Inc (NYSE:STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE:ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation systems.
Stereotaxis 纽约证券交易所代码：STXS）宣布与该公司进行全球合作后，股价上涨 雅培实验室 （纽约证券交易所代码：ABT）将雅培的enSite X EP系统与Stereotaxis的机器人磁导航系统集成。
Stereotaxis and Abbott have completed the integration of their technologies and performed testing demonstrating joint compatibility.
Stereotaxis和Abbott已经完成了其技术的整合，并进行了测试，证明了联合兼容性。
The integrated technologies are cleared for use in Europe, with additional regulatory clearances expected in the coming months.
集成技术已获准在欧洲使用，预计未来几个月将获得更多监管许可。
Concurrently, the FDA approved Abbott's TactiFlex Ablation Catheter, Sensor Enabled. The company says it is the world's first ablation catheter with a flexible tip and contact force technology.
同时，美国食品药品管理局批准了雅培的TactiFlex消融导管，支持传感器。该公司表示，这是世界上第一款采用柔性尖端和接触力技术的消融导管。
It is used to perform an ablation procedure to treat atrial fibrillation (AFib), the most common abnormal heart rhythm. The TactiFlex catheter can result in reduced procedure times and better safety than the company's previous-generation catheters.
它用于进行消融手术以治疗心房颤动 (Afib)，这是最常见的心律异常。与该公司的上一代导管相比，TactiFlex导管可以缩短手术时间并提高安全性。
The TactiFlex catheter uses a tip design with a laser-cut pattern that flexes when in contact with the heart wall, thus helping direct fluid to the treated tissue and allowing for more accurate positioning of the catheter – providing up to two times higher stability in a beating heart – for consistent therapy delivery.
TactiFlex 导管采用具有激光切割图案的尖端设计，该图案在与心脏壁接触时会弯曲，从而有助于将液体引导到治疗后的组织，并允许更准确地定位导管，从而在跳动的心脏中提供高达两倍的稳定性，从而实现稳定的治疗。
Tuesday, the FDA approved Abbott's spinal cord stimulation devices for chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
周二，美国食品药品管理局批准了 雅培的 脊髓刺激设备，用于治疗未接受或没有资格接受背部手术的人的慢性背部疼痛，称为非手术性背部疼痛。
Price Action: STXS shares are up 34.7% at $2.28, and ABT shares are up 0.34% at $108.84 on the last check Friday.
价格走势： 在周五的最后一张支票中，STXS股价上涨34.7％，至2.28美元，ABT股价上涨0.34％，至108.84美元。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧